Natamycin in the treatment of keratomycosis: Correlation of treatment outcome and in vitro susceptibility of fungal isolates

Indian Journal of Ophthalmology

Volumn 59, Issue 6, 2011, Pages 512-514

  Pradhan, Linu ^a   Sharma, Savitri ^a   Nalamada, Suma ^a   Sahu, Srikant K ^a   Das, Sujata ^a   Garg, Prashant ^a  

^a L V PRASAD EYE INSTITUTE   (India)

Author keywords

Keratomycosis; minimum inhibitory concentration; natamycin; susceptibility; treatment outcome

Indexed keywords

ANTIFUNGAL AGENT; EYE DROPS; NATAMYCIN;

ANTIFUNGAL RESISTANCE; ARTICLE; CLINICAL TRIAL; FUNGAL EYE INFECTION; HUMAN; KERATITIS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PROSPECTIVE STUDY;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; EYE INFECTIONS, FUNGAL; HUMANS; KERATITIS; MICROBIAL SENSITIVITY TESTS; NATAMYCIN; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES;

EID: 80155213946     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.86328     Document Type: Article

References (11)

1. Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol 2004;15: 321-7. (Pubitemid 38962112)
2. Thomas PA. Current perspective in ophthalmic mycosis. Clin Microbiol Rev 2003;16:730-97.
3. Goinathan U, Sharma S, Garg P, Rao GN. Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: Experience of over a decade. Indian J Ophthalmol 2009;57:273-9.
4. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002;35:982-9. (Pubitemid 35178316)
5. Gopinathan U, Garg P, Fernandes M, Sharma S, Sreedharan A, Rao GN. The epidemiological features and laboratory results of fungal keratitis: A 10-year review at a referral eye care center in south India. Cornea 2002;21:555-9. (Pubitemid 34803656)
6. Shapiro BL, Lalitha P, Loh AR, Fothergill AW, Prajna NV, Srinivasan M, et al. Susceptibility testing and clinicaloutcome in fungal keratitis. Br J Ophthalmol 2010;94:383-4.
7. Lalitha P, Vijaykumar R, Prajna NV, Fothergill AW. In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: Comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder. J Clin Microbiol 2008;46:3477-8.
8. Lalitha P, Prajna NV, Kabra A, Mahadevan K, Srinivasan M. Risk factors for treatment outcome in fungal keratitis. Ophthalmology 2006;113:526-30.
9. Tavanti A, Hensgens LA, Mogavero S, Majoros L, Senesi S, Campa M. Genotypic and phenotypic properties of Candida parapsilosis sensu strictu strains isolated from diff erent geographic regions and body sites. BMC Microbiol 2010;10:203.
10. Leema G, Kaliamurthy J, Geraldine P, Thomas PA. Keratitis due to Aspergillus fl avus: Clinical profi le, molecular identifi cation of fungal strains and detection of afl atoxin production. Mol Vis 2010;16:843-54.
11. Vemuganti GK, Garg P, Gopinathan U, Naduvilath TJ, John RK, Rajeev B, et al. Evaluation of agent and host factors in progression of mycotic keratitis: A histological and microbiological study of 167 butt ons. Ophthalmology 2002;109:1538-46.